ArticleProstate cancer2026
Change in Clinical Management of Localized Prostate Cancer Patients at a Tertiary Medical Center as a Result of SARS-CoV-2 (COVID-19).
Article in Prostate cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: At the height of the COVID-19 pandemic, healthcare utilization among cancer patients, including those with prostate cancer, was limited due to inadequate healthcare resources and concern for disease transmission among patients and medical personnel. While publications with treatment recommendations during the pandemic exist, there is limited real-life data comparing prostate cancer management pre-COVID to during the pandemic. Objective: The primary aim of this study is to determine the effect of the COVID-19 pandemic on prostate cancer management at a tertiary medical center by comparing patients receiving treatment preceding the pandemic to those receiving treatment during the height of the pandemic. Methods: Prostate cancer patients treated with definitive intent (surgery, definitive radiation (RT), or salvage RT) in 2019-2020 were retrospectively reviewed. Analysis was performed with the following timeframes: pre-COVID as 1/3/19 to 2/28/20 and COVID as 3/1/20 to 9/30/20. Time-to-treatment (TT) for surgery and definitive RT was defined from the date of diagnosis (biopsy or decision to treat if active surveillance) to the date of surgery or RT start, respectively. TT for salvage RT was defined as the date of PSA failure to RT start. Descriptive statistics such as medians and interquartile ranges (IQRs) were reported for continuous variables, while frequency counts and percents were reported for categorical variables. Chi-squared tests (Fisher's exact when appropriate) along with Wilcoxon rank sum tests were used to compare two timeframes. Two adjusted binary logistic regressions assessed the associations of NCCN risk groups, as well as grade group (GG), on the outcome of receipt of treatment during COVID compared to those in pre-COVID timeframes. Results: This study sample included 565 prostate cancer patients treated with surgery ( Conclusions: The COVID-19 pandemic changed prostate cancer management in various ways including longer TT, prolonged time from ADT initiation to RT, increased utilization of ADT for patients planned for surgery, and prioritizing treatment for higher-risk disease. Analysis of treatment outcomes for these patients may direct action in future global pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.